IGC Pharma, Inc.
IGC- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001326205
No open-market purchases or sales by IGC Pharma, Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $1.41M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in IGC Pharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −3 vs. Q4 2022
- Shares held
- 2.71M
- −241.9K (−8.2%) vs. Q4 2022
- Total value
- $917.6K
- −$19.7K (−2.1%) vs. Q4 2022
- New holders
- 2
- 6 more added
- Sold out
- 5
- 5 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IGC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 36 | $1.41M |
| Q1 2026 | 35 | $1.14M |
| Q4 2025 | 30 | $1.36M |
| Q3 2025 | 35 | $2.27M |
| Q2 2025 | 28 | $929.4K |
| Q1 2025 | 25 | $814.9K |
| Q4 2024 | 30 | $954.3K |
| Q3 2024 | 23 | $1.19M |
| Q2 2024 | 25 | $1.11M |
| Q1 2024 | 25 | $943.4K |
| Q4 2023 | 25 | $691.3K |
| Q3 2023 | 27 | $1.01M |
| Q2 2023 | 23 | $827.5K |
| Q1 2023 | 23 | $917.6K |
| Q4 2022 | 26 | $937.3K |
| Q3 2022 | 26 | $1.31M |
| Q2 2022 | 29 | $1.73M |
| Q1 2022 | 29 | $3.97M |
| Q4 2021 | 29 | $6.07M |
| Q3 2021 | 32 | $7.90M |
| Q2 2021 | 29 | $7.90M |
| Q1 2021 | 29 | $7.97M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding IGC Pharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 755,862 | $256.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 646,543 | $219.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 302,140 | $102.6K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 184,107 | $62.5K | 0.00% | 00.0% | Unchanged |
| Dearborn Partners LLC | 116,710 | $39.6K | 0.00% | −17,691−13.2% | Reduced |
| Renaissance Technologies LLC | 110,300 | $37.0K | 0.00% | −111,711−50.3% | Reduced |
| Millennium Management LLC | 103,783 | $35.0K | 0.00% | −40,941−28.3% | Reduced |
| Susquehanna International Group, LLP | 88,722 | $30.1K | 0.00% | +10,582+13.5% | Added |
| Northern Trust Corp | 71,364 | $24.2K | 0.00% | +8,036+12.7% | Added |
| Bridgeway Capital Management, LLC | 69,000 | $23.4K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 65,503 | $22.2K | 0.00% | +100.0% | Added |
| Group One Trading, L.P. | 60,156 | $20.4K | 0.00% | +11,400+23.4% | Added |
| Commonwealth Equity Services, LLC | 53,156 | $18.0K | 0.00% | −650−1.2% | Reduced |
| Truist Financial Corp | 36,667 | $12.4K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 20,795 | $7.00K | 0.00% | +10,703+106.1% | Added |
| Jane Street Group, LLC | 15,610 | $5.30K | 0.00% | −22,688−59.2% | Reduced |
| Geneos Wealth Management Inc. | 3,000 | $1.02K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 810 | $275 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 341 | $116 | 0.00% | +5+1.5% | Added |
| UBS Group AG | 294 | $100 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 232 | $78 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 20 | $7 | 0.00% | +20 | New |
| Toronto Dominion Bank | 6 | $0 | 0.00% | +6 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −65,152−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −22,466−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |